How ValueAct could assist increase margins at this Japanese medical gadget firm

Firm: Nihon Kohden (6849.T-JP)

Enterprise: Nihon Kohden is a Japan-based firm engaged within the analysis, improvement, manufacture and sale of medical digital tools, in addition to the availability of upkeep and restore companies. The corporate affords a wide selection of units to help with medical diagnoses, together with electroencephalographs, evoked potential testing tools, electrocardiographs, cardiac catheterization tools, diagnostic data programs and associated consumables. The corporate can be engaged within the gross sales promotion for its merchandise, in addition to the final affair-related and manpower dispatching companies.

That is the third Japanese medical gadget firm ValueAct has invested in. Notably, the agency invested in Olympus in 2017, obtained a board seat in 2019 and stays on the board right this moment. Each Olympus and Nihon Kohden are international medical gadget corporations. Nevertheless, Olympus derives 80% of its income from exterior of Japan, whereas Nihon Kohden will get roughly 40% of its income from exterior of Japan. Nevertheless, each corporations have glorious merchandise and an ambition to be international, and Nihon Kohden may observe a path to globalization that is just like the one Olympus has taken.

There are three major levers for worth technology at Nihon Kohden: working margin enlargement, optimizing the combination of kit versus consumables and companies income, and disciplined capital allocation. First, regardless of having 51% gross revenue margins, Nihon Kohden’s working margins are solely at 10%, whereas opponents in each Japan and overseas are within the mid to excessive teenagers. With roughly 60% market share in Japan, the place a few of its income comes from distributing third-party merchandise, and 10% market share within the U.S., the place the corporate has proprietary merchandise, the expansion and margin potential is larger within the U.S. Nihon Kohden can use its reputational energy to capitalize on the U.S. market. The corporate has a chance to shortly get to fifteen% working margins inside a couple of years and may see incremental enchancment in following years.  

Second, Nihon Kohden has traditionally been centered on {hardware} gross sales and its income is break up roughly evenly between {hardware} and consumables and companies. Nevertheless, there is a chance for worth creation if the corporate pursues a method to extend its income from consumables and companies because of the recurring nature and better margins of that sort of income. From these two methods alone, Nihon Kohden can drive 20% revenue development over the following three years.

Third, the corporate is at present sitting on web money equal to about 15% of its market cap. Like many Japanese corporations, Nihon Kohden may create worth from an accretive capital deployment technique that evaluates returning capital to shareholders or disciplined M&A. Traditionally, shopping for again shares hasn’t been a well-liked tactic in Japan, however share repurchases have been growing over current years. The Tokyo Inventory Alternate has been encouraging them as a part of a course of to get corporations to commerce over one instances guide worth.  

ValueAct has an earned fame as a collaborative and amicable activist, and there’s no purpose why this case needs to be any completely different. Earlier than increase such a place, ValueAct probably has been attending to know administration over the previous yr and spent appreciable time with CEO Hirokazu Ogino. Furthermore, ValueAct wouldn’t have made this funding if the agency didn’t have a excessive diploma of respect for Ogino and the remainder of the administration group. We count on that ValueAct and administration are aligned on their views, notably with respect to margin enchancment and capital allocation.

ValueAct doesn’t take board seats by concern or power, however organically through dialogue and concord. Accordingly, we’d count on the agency to proceed to assist administration as an lively shareholder and solely take a board seat at a time that each ValueAct and administration really feel the investor may add worth. At Olympus, that took two years. At JSR, it took over a yr. Each corporations have been extremely profitable engagements for them, returning 109.48% at Olympus versus 7.68% for the MSCI EAFE, and 116.86% at JSR versus 38.57% for the MSCI EAFE. ValueAct remains to be on the board at each corporations. The same final result right here may end up in nearly a doubling of the inventory in two to 3 years.

Ken Squire is the founder and president of 13D Monitor, an institutional analysis service on shareholder activism, and the founder and portfolio supervisor of the 13D Activist Fund, a mutual fund that invests in a portfolio of activist 13D investments.